Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.67)
# 191
Out of 5,182 analysts
26
Total ratings
60.71%
Success rate
48.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CING Cingulate | Maintains: Buy | $16 → $14 | $5.47 | +155.94% | 5 | Mar 23, 2026 | |
| CRVO CervoMed | Maintains: Buy | $19 → $11 | $3.88 | +183.51% | 5 | Mar 18, 2026 | |
| NRSN NeuroSense Therapeutics | Initiates: Buy | $3 | $0.75 | +299.95% | 1 | Mar 10, 2026 | |
| OVID Ovid Therapeutics | Initiates: Buy | $3 | $2.60 | +15.38% | 1 | Dec 11, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $4.62 | +94.81% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $35.27 | -63.14% | 3 | Nov 12, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $140 → $60 | $0.90 | +6,563.71% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.94 | +219.15% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $1.97 | +204.57% | 3 | Aug 13, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $12.63 | +129.61% | 1 | Dec 5, 2024 |
Cingulate
Mar 23, 2026
Maintains: Buy
Price Target: $16 → $14
Current: $5.47
Upside: +155.94%
CervoMed
Mar 18, 2026
Maintains: Buy
Price Target: $19 → $11
Current: $3.88
Upside: +183.51%
NeuroSense Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $3
Current: $0.75
Upside: +299.95%
Ovid Therapeutics
Dec 11, 2025
Initiates: Buy
Price Target: $3
Current: $2.60
Upside: +15.38%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.62
Upside: +94.81%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $35.27
Upside: -63.14%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $140 → $60
Current: $0.90
Upside: +6,563.71%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.94
Upside: +219.15%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.97
Upside: +204.57%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $12.63
Upside: +129.61%